Ruitao Lin

1.9k total citations
72 papers, 1.0k citations indexed

About

Ruitao Lin is a scholar working on Statistics and Probability, Management Science and Operations Research and Economics and Econometrics. According to data from OpenAlex, Ruitao Lin has authored 72 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Statistics and Probability, 29 papers in Management Science and Operations Research and 14 papers in Economics and Econometrics. Recurrent topics in Ruitao Lin's work include Statistical Methods in Clinical Trials (44 papers), Optimal Experimental Design Methods (29 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Ruitao Lin is often cited by papers focused on Statistical Methods in Clinical Trials (44 papers), Optimal Experimental Design Methods (29 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Ruitao Lin collaborates with scholars based in United States, China and Hong Kong. Ruitao Lin's co-authors include Guosheng Yin, Ying Yuan, Daniel Li, Yanhong Zhou, Peter F. Thall, Hai Ming Wong, Yi Feng Wen, Fangrong Yan, Katherine E. Warren and Lei Nie and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Ruitao Lin

60 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruitao Lin United States 17 558 305 173 157 151 72 1.0k
Hoang Q. Nguyen United States 15 388 0.7× 215 0.7× 133 0.8× 316 2.0× 127 0.8× 23 995
Nolan A. Wages United States 19 570 1.0× 330 1.1× 134 0.8× 33 0.2× 403 2.7× 96 1.2k
Jianchang Lin United States 18 276 0.5× 87 0.3× 85 0.5× 182 1.2× 395 2.6× 84 1.0k
Martin Jenkins United Kingdom 16 192 0.3× 84 0.3× 65 0.4× 33 0.2× 150 1.0× 54 956
Jared C. Foster United States 12 331 0.6× 28 0.1× 115 0.7× 58 0.4× 364 2.4× 27 928
M N Chang United States 13 140 0.3× 74 0.2× 36 0.2× 392 2.5× 263 1.7× 20 951
Zheng Yuan United States 12 280 0.5× 125 0.4× 85 0.5× 31 0.2× 31 0.2× 22 526
Kevin J. Carroll United Kingdom 12 161 0.3× 22 0.1× 87 0.5× 51 0.3× 88 0.6× 26 654
Zhihong Cai Japan 14 155 0.3× 22 0.1× 53 0.3× 86 0.5× 145 1.0× 65 791
Hongkun Wang United States 16 51 0.1× 20 0.1× 59 0.3× 41 0.3× 186 1.2× 61 588

Countries citing papers authored by Ruitao Lin

Since Specialization
Citations

This map shows the geographic impact of Ruitao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruitao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruitao Lin more than expected).

Fields of papers citing papers by Ruitao Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruitao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruitao Lin. The network helps show where Ruitao Lin may publish in the future.

Co-authorship network of co-authors of Ruitao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Ruitao Lin. A scholar is included among the top collaborators of Ruitao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruitao Lin. Ruitao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Meng, Rahul K. Shah, Ruitao Lin, et al.. (2025). Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019. Blood Advances. 10(5). 1713–1721.
3.
Lin, Ruitao, et al.. (2024). On the relative conservativeness of Bayesian logistic regression method in oncology dose‐finding studies. Pharmaceutical Statistics. 23(4). 585–594. 1 indexed citations
4.
Lin, Ruitao, et al.. (2024). Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical Trials. 21(3). 308–321. 2 indexed citations
5.
Lin, Ruitao, et al.. (2024). A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical Methods in Medical Research. 33(6). 931–944.
6.
Lin, Lilie L., Franklin C. Wong, Ruitao Lin, Timothy A. Yap, & Jennifer K. Litton. (2024). Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib. JCO Precision Oncology. 8(8). e2400303–e2400303.
7.
Liu, Rong, Ying Yuan, Qing Jiang, et al.. (2024). Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective. Statistics in Biopharmaceutical Research. 16(3). 338–347.
8.
Yuan, Ying, et al.. (2024). Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials. Statistics in Biopharmaceutical Research. 17(2). 266–276. 1 indexed citations
9.
Lin, Ruitao, et al.. (2024). Comparative review of novel model‐assisted designs for phase I/II clinical trials. Biometrical Journal. 66(4). e2300398–e2300398. 3 indexed citations
10.
Yuan, Ying, et al.. (2024). A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal. 66(2). e2300122–e2300122.
11.
Li, Zeng, et al.. (2023). On singular values of large dimensional lag-τ sample auto-correlation matrices. Journal of Multivariate Analysis. 197. 105205–105205. 1 indexed citations
12.
Thall, Peter F., Yong Zang, Andrew G. Chapple, et al.. (2023). Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clinical Cancer Research. 29(22). 4549–4554. 4 indexed citations
13.
Liu, Rong, Ying Yuan, Qi Jiang, et al.. (2022). Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research. 14(3). 270–282. 7 indexed citations
14.
Cao, Jiguo, et al.. (2021). uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials. Statistics in Medicine. 40(11). 2626–2649. 14 indexed citations
15.
Lin, Ruitao, et al.. (2021). Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. Biostatistics. 24(2). 277–294. 13 indexed citations
16.
Oran, Betül, Marcos de Lima, Guillermo Garcia‐Manero, et al.. (2020). A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances. 4(21). 5580–5588. 132 indexed citations
17.
Lin, Ruitao, Yanhong Zhou, Fangrong Yan, Daniel Li, & Ying Yuan. (2020). BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology. 4(4). 1393–1402. 80 indexed citations
18.
Lin, Ruitao, Peter F. Thall, & Ying Yuan. (2019). An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes. Biometrics. 76(1). 304–315. 14 indexed citations
19.
Yuan, Ying, Ruitao Lin, Daniel Li, Lei Nie, & Katherine E. Warren. (2018). Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research. 24(20). 4921–4930. 84 indexed citations
20.
Lin, Ruitao, et al.. (2016). Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics & Data Analysis. 104. 10–23. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hoang Q. Nguyen Breakdown of academic impact, for papers by Nolan A. Wages Breakdown of academic impact, for papers by Jianchang Lin Breakdown of academic impact, for papers by Martin Jenkins Breakdown of academic impact, for papers by Jared C. Foster Breakdown of academic impact, for papers by M N Chang Breakdown of academic impact, for papers by Zheng Yuan Breakdown of academic impact, for papers by Kevin J. Carroll Breakdown of academic impact, for papers by Zhihong Cai Breakdown of academic impact, for papers by Hongkun Wang
Rankless by CCL
2026